Roche Presents New Phase III One-year Data for Vamikibart in Uveitic Macular Edema, a Serious Cause of Vision Loss
October 13, 2026
October 13, 2026
BASEL, Switzerland, Oct. 13 (TNSjou) -- Roche, a biotech company, issued the following news release:
* * *
Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
* In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks/1,2
* UME is the leading cause of moderate and severe vi . . .
* * *
Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
* In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks/1,2
* UME is the leading cause of moderate and severe vi . . .